CIK 0001604464
- Non-accelerated filer
- Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460920988
- Phone
- +1 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- Open-market buys, last 90 days
- $999,994
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$999,994. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-08-15 | MCGRATH JOHN EVP & Chief Financial Officer | Option exercise · Restricted Stock Units | −7,697 | 12,829 | ||
| 2017-08-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Option exercise | +829 | 362,909 | ||
| 2017-08-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −7,604 | $14.75 | $112K | 355,305 |
| 2017-08-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Option exercise · Restricted Stock Units | −829 | 1,382 | ||
| 2017-08-15 | Clark Mitchall G. EVP & Chief R & QA Officer | Option exercise | +7,211 | 162,151 | ||
| 2017-08-15 | Clark Mitchall G. EVP & Chief R & QA Officer | Option exercise · Restricted Stock Unites | −7,211 | 19,231 | ||
| 2017-08-15 | Ciechanover Isaac E. Chief Executive Officer | Option exercise | +5,908 | 737,767 | ||
| 2017-08-15 | Ciechanover Isaac E. Chief Executive Officer | Option exercise · Restricted Stock Units | −5,908 | 9,846 | ||
| 2017-08-11 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $14.58 | $32K | 446,178 |
| 2017-08-10 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $14.75 | $32K | 448,378 |
| 2017-07-25 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,500 | $15.97 | $40K | 450,778 |
| 2017-07-25 | Ciechanover Isaac E. Chief Executive Officer | Sale | −200 | $16.79 | $3K | 450,578 |
| 2017-07-24 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,500 | $16.89 | $42K | 453,578 |
| 2017-07-24 | Ciechanover Isaac E. Chief Executive Officer | Sale | −300 | $17.32 | $5K | 453,278 |
| 2017-07-17 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −6,000 | $14.92 | $90K | 362,080 |
| 2017-06-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −6,000 | $12.65 | $76K | 368,080 |
| 2017-06-09 | Gallagher Carol Giltner Director | Sale | −1,000 | $13.15 | $13K | 107,374 |
| 2017-06-08 | SEIDENBERG BETH C Director | Grant or award | +5,000 | 13,689 | ||
| 2017-06-08 | SEIDENBERG BETH C Director | Grant or award · NonQualified Stock Option (Right to Buy) | +21,500 | 21,500 | ||
| 2017-06-08 | Gallagher Carol Giltner Director | Grant or award | +5,000 | 108,374 |
Page 42 of 44 · 867 trades